Formulation for a protein pharmaceutical without added human serum albumin (HSA)
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
C07K-014/00
출원번호
UP-0565111
(2004-07-22)
등록번호
US-7829525
(2010-11-25)
우선권정보
DE-103 33 317(2003-07-22)
국제출원번호
PCT/DE2004/001635
(2004-07-22)
§371/§102 date
20070219
(20070219)
국제공개번호
WO05/007185
(2005-01-27)
발명자
/ 주소
Frevert, Jürgen
출원인 / 주소
Merz Pharma GmbH & Co. KGaA
대리인 / 주소
Fulbright & Jaworski L.L.P.
인용정보
피인용 횟수 :
19인용 특허 :
5
초록▼
A composition for stabilization of protein agents in pharmaceuticals, the composition comprising the following two constituents: a) a surface active substance, in particular a non-ionic detergent (tenside), and b) a mixture of at least two amino acids, wherein the at least
A composition for stabilization of protein agents in pharmaceuticals, the composition comprising the following two constituents: a) a surface active substance, in particular a non-ionic detergent (tenside), and b) a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn.
대표청구항▼
The invention claimed is: 1. A composition free of human serum albumin for stabilization of protein agents in pharmaceuticals, the composition comprising the following constituents: a) a surface active substance, and b) a mixture of at least two amino acids, wherein the at least two amino acids are
The invention claimed is: 1. A composition free of human serum albumin for stabilization of protein agents in pharmaceuticals, the composition comprising the following constituents: a) a surface active substance, and b) a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn. 2. The composition according to claim 1, further comprising at least one of the following constituents selected from the group consisting of a sucrose, trehalose, lactose, ethylenediaminetetraacetic acid (EDTA), and a salt of EDTA. 3. The composition according to claim 2, comprising anyone of the following constituent groups: a) a surface active substance, a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn, and at least one of sucrose, trehalose, or lactose, b) a surface active substance, a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn, and EDTA or a salt of EDTA c) a surface active substance, a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn, and at least one of sucrose, trehalose, lactose, EDTA, or a salt of EDTA. 4. The composition according to claim 1, wherein the composition is either soluble in aqueous media or is present as aqueous solution. 5. A pharmaceutical composition comprising a protein agent and a composition free of human serum albumin for stabilization of protein agents in pharmaceuticals, the composition comprising the following constituents: a) a surface active substance, and b) a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn. 6. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is present as a freeze-dried or vacuum-dried powder, which is soluble in aqueous media. 7. The pharmaceutical composition according to claim 5, wherein the protein agent is a coagulation factor, a cytokine, an enzyme, a plasminogen activator, an ultra pure neurotoxin or a neurotoxin complex. 8. The composition for stabilization according to claim 1, wherein the at least two amino acids are (i) aspartic acid, asparagine, glutamic acid; (ii) aspartic acid, asparagine, glutamine; (iii) aspartic acid, glutamic acid, glutamine; (iv) asparagine, glutamic acid, glutamine; or (v) aspartic acid, asparagine, glutamic acid and glutamine. 9. The pharmaceutical composition according to claim 8, wherein the concentrations of the individual amino acids are in each case 20 to 200 mM. 10. The pharmaceutical composition according to claim 8, wherein the surface active substance is a non-ionic detergent. 11. The pharmaceutical composition according to claim 10, wherein the non-ionic detergent is a polysorbate or a poloxamer. 12. The pharmaceutical composition according to claim 8, wherein the disaccharide is sucrose, trehalose or lactose. 13. The pharmaceutical composition according to claim 8, wherein the pH value of the composition in solution is 5.0 to 8.5. 14. The pharmaceutical composition of claim 5, wherein the at least two amino acids are (i) aspartic acid, asparagine, glutamic acid; (ii) aspartic acid, asparagine, glutamine; (iii) aspartic acid, glutamic acid, glutamine; (iv) asparagine, glutamic acid, glutamine; or (v) aspartic acid, asparagine, glutamic acid and glutamine. 15. The pharmaceutical composition according to claim 13, wherein the pH value of the composition in solution is 6.0 to 8.0. 16. The pharmaceutical composition according to claim 13, wherein the pH value of the composition in solution is 6.0 to 7.0. 17. The pharmaceutical composition according to claim 13, wherein the pH value of the composition in solution is 6.5. 18. The pharmaceutical composition according to claim 11, wherein the polysorbate or poloxamer is polysorbate 20, polysorbate 80, poloxamer 184, or poloxamer 188. 19. The composition of claim 1, wherein the surface active agent is a non-ionic detergent. 20. The composition of claim 19, wherein the non-ionic detergent is tenside. 21. The composition of claim 5, wherein the surface active agent is a non-ionic detergent. 22. The composition of claim 21, wherein the non-ionic detergent is tenside.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (5)
Adjei Akwete ; Cutie Anthony J., Amino acid stabilized medical aerosol formulation.
Kotitschke Ronald (Dreieich DEX) Stephan Wolfgang (Dreieich DEX), Method for the cold sterilization of preparations containing blood coagulation factor VIII.
Zeng, Li; Mitra, Rohini; Rossi, Edmund A.; Hansen, Hans J.; Goldenberg, David M., Stable compositions of high-concentration allotype-selected antibodies for small-volume administration.
Zeng, Li; Mitra, Rohini; Rossi, Edmund A.; Hansen, Hans J.; Goldenberg, David M., Stable compositions of high-concentration allotype-selected antibodies for small-volume administration.
Zeng, Li; Mitra, Rohini; Rossi, Edmund A.; Hansen, Hans J.; Goldenberg, David M., Stable compositions of high-concentration allotype-selected antibodies for small-volume administration.
Zeng, Li; Mitra, Rohini; Rossi, Edmund A.; Hansen, Hans J.; Goldenberg, David M., Ultrafiltration concentration of allotype selected antibodies for small-volume administration.
Zeng, Li; Mitra, Rohini; Rossi, Edmund A.; Hansen, Hans J.; Goldenberg, David M., Ultrafiltration concentration of allotype selected antibodies for small-volume administration.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.